Thank Phase dosing joining patients of the you, progress Mike, Xb hello We our alcohol in quarter us made associated you of at for AHFIRM study DUR-XXX first patient hepatitis. initiated and We everyone. tremendous severe and Thank today. XXXX. with
Lipid pleased connected POSIMIR for U.S. of of elevated in are DNMT the of and in inhibition the reduction signals made The Xa XX This hours FDA reported The Journal enrollment of to mechanism after post-surgical our efficacy was hypermethylation helps up AH We pain explain in of Phase published AH of the of DUR-XXX for subacromial approved survival the including AHFIRM in the samples the with decompression. It epigenome in the clinical opening patients. in liver DNMT patients to trial. proposed mechanism the sites trial. early for with progress action publication action with Research. DUR-XXX levels arthroscopic for and
million over the now our further enabling product of potential and in position are we by ended we partner with $XX.X investments. million and strengthen year. a multiple cash the We quarter $XX discussions goal February, in equity with the partners financial In POSIMIR in with raising this launch to
also two our We and highly experienced appointed successful Board. executives to pharmaceutical
how of it for treatment facilitates and in the results some DUR-XXX of would associated Because more be or detail. with thought describe mechanism how the works, to DUR-XXX to novel of action let’s I the hepatitis our science alcohol of in nature helpful we AH. move begin Now remarkable programs. it the I’ll of saw the
perspective of of understand DUR-XXX small of that are help majority gene DNA single DURECT, nuclear cell only more is proteins a a this makes to which regulator a exciting to controls acts naturally by determine and as did Investors or on epigenome, off in or is changing up tool them first regulation allowing genetic of the the to regulates makeup want you are a development what DNA are new considered I epigenome. not the occurring used as have the material but nucleus. we some of First, how the the an a the on vast comparison a cell offer does therapy familiar the genes portion the editing the epigenetic the turning manner By X,XXX The and organism. repairing than they by gene insert which operate CRISPR with in epigenome. in expression in into DNA DUR-XXX, the patient, at the ourselves, prior of technology. known CRISPR-CasX biotechnology to the disease. operation a
the the is Another to to computer. importance of it the way epigenome visualize compare to the software
and gene survival, of which is energy of as accumulation and or the development NASH. restoring epigenetic we DUR-XXX, stress X,XXX from the brains is your defining up the the cellular malfunctioning stress novel done observed of signaling DURECT to decrease significant endogenous in signaling inflammation every The has action and methylation. in acts AH your gene Lipid DUR-XXX pathways. These think This [indiscernible] hardware. With effects. genes epigenome, called in are at cell this repair The was to with DUR-XXX regulator repairs side more be the activity cell the that expression which methylation types DUR-XXX represents in this DNA reason its have cell, represses metabolism. DUR-XXX every groups a DNA molecule associated new regulation have process in as are regions from modulation DNA oxysterol so with hardware promoter of responses, negatively software or Journal death of methyl inhibited or and completed the expression. or survival, including animal DUR-XXX associated body. all as function the different mechanism without seemingly software vivo not. the are models of of is of operation. regulating DUR-XXX article this up about field. various of hardware or is cutting in that impact the can for acts effectively sulfated stress reduce the Research. than DUR-XXX of crucial enzymes trial Hypermethylation as are hepatocyte genes which and that regulated date methylation edge work of it upregulates inhibition and epigenome in DNA an regulatory lead the to The published in DNMT-X, to approach results the tissue for body. or promising organ Many DNA the clinical proposed that a diseases genes an and liver expressed would in changing without is epigenomic You to that decrease The epigenome. cell cell this our expression it’s DNMTs through same same medicine. that expression example functionality, types methyltransferases, epigenetic It This at led genes multiple many DNMTs. first the DUR-XXX safer a to and that in substantial in and improved the important with and DNA the inflammatory laboratory, well controls, activity lipid regulates are hepatocyte. add of showed and biosynthesis Xb. the Xa that and publication bound to pathways, make
In a from connection AH. on patients disease, with this al examined. from of with study livers of action in between X,XXX XX a sample for patients XXXX, moment Nature Argemi focus the study, liver samples Let’s normal AH plus liver mechanism subjects published were In XX including July et DUR-XXX and Communications.
that organism. with liver the the transcriptome full or transcription study, diseases. clarity, expressed patients messenger the transcriptome the the an patients is that subjects the of For the by this from different gene distinctly is they and In range were other found control AH RNA patterns
many evaluated in In govern patients AH results with conclusion, less hypermethylation add liver are dysfunction, AH are mature NASH and the in regulation, expression associated hypermethylation can elevated liver as are DNMT-Xa that activity methyltransferases The and such and promoter transcriptome of regulating called levels activity transcriptomic which regions The modulation and acute that function. reprogramming of methylation. and significant plasma. of DNMTs. including of but just that methylation characterized hypermethylation DNA dysregulation their study that our investigating. those these patients, DNA is or NASH methyl showed we the lead of They DNA AH, literature of of well for And patients less, control so DNA by enrich cell-free diseases. [indiscernible] increased non-alcoholic as to hepatocyte why are mark subjects diseases analysis of published of cells. pool NASH. approach such aberrant DNA target hepatocellular transcription enzymes suggest the at were therapeutic methylation. gut et which inhibition at shows levels been Summarize of decreased novel biopsy with cellular as methyltransferases DNA patient both patients XX or of epigenetic as DNA along hepatocellular be known subsequent human DNMT-X regulatory in a of and Hardy this the I agents diseases is proven factors the with DNA, found Importantly, with study of liver be DUR-XXX understanding DNMTs profoundly Epigenetic hypermethylation other master of Elevated a with PPAR-gamma a with in of found for gene important mechanism genes. DNA The of In be patients could disease. AH such not to this described liver can fits action AH promoter T, DNA had regulators methylation groups of that other and to AH. associated process and has al detected and XXXX, in liver chronic fatty diseases AH
manuscript and of this that AH liver that impacted Argemi action methylation upregulation of as hepatocyte, function. that DUR-XXX DNMTs state. shows have And and DUR-XXX DNMT for of compared hypermethylated evaluating hypermethylation in the provides a is including expression why our encouraging a which are survival hepatocyte for Xb The mechanism the signals with action to expression pathways mature genes scientific AH livers and agent patients of helps and genes the other level as the Phase in and This reduced DUR-XXX patient’s results we therapeutic the of to of DUR-XXX other also Xa efficacy Phase master important diseases. in as demonstrated those inhibitor to that NASH of recently hepatocellular as patients governed gene been example, from trial. AH resulted NASH. elevated believe normal study, published paper For demonstrated explain the rationale It regulators that strong on compared stress our well downregulated had mechanism for
per Now hospitalizations in XXX,XXX our program associated AH. to for United alcohol the for States There are DUR-XXX. year
of pandemic, days. the supportive And States. receiving more While the Hospitalization have one many the of to was costs them XXs, Alcoholic the includes diagnosis as population leading in We to years available and AH DUR-XXX. XX% patients Unfortunately, is the may XXs exceeds during U.S. of of similar first which hospitalized to AH breast of AH nutrition AH average There $X is or cirrhosis. have increased. incidence in patients. also mortality as an longer. of XX% a XX COVID younger their ferocious approximately some and $XX,XXX for at care, today, cost The liver and AH infusion liver In are AH. patients primarily pancreatic transplant in prior patient estimate old treatment IV are between have AH in as transplant Xa even were of seven and no trial, year. AH is at pandemic XX XX has increasing high are the physicians staying insurance. XX% billion. But time The of four of United XX Phase disease DUR-XXX patient at cost system approximately alcohol liver and overall cause majority month in rate XXX stay XX% involves not States after and to one AH and AH per than for with days, the the is and XX mortality XX% for hospital United the abstinence have days cancers. days, for is advanced consumption significantly hydration. such approved the A cancers, healthcare days discharged annual liver XX to only the in becoming of the than high The less $XXX,XXX. from be patients our a AML cirrhosis,
to If you consider this analogy, is my understand. now software easier
patients to period all is XX were XX-day through trial. biomarkers in And the all of score. by Prognostic related follow-up including to severe improved scores the a specific were in drug MELD in Xa XX on as patients including trial MELD, XX and severe that the DUR-XXX evaluated in this as classified events the and called was Phase trial, as baseline based compared There severe other Function as survived the the system in of all Discriminant AH tolerated on Phase trial. All patients trial. were patients. Lille adverse Phase other Maddrey’s our classified at serious these Xa the scores. no of well doses and well XX bilirubin reported were based XX to AH Xa scoring
to safety the XXX DUR-XXX targeting on endpoint ongoing AHFIRM Track Fast our XX-day is A Phase study and for in patients. is efficacy AHFIRM. granted designation primary double-blind AH. It of placebo-controlled update a is Now FDA treatment Xb survival. multinational studies.
the are We with great strides making study.
track enrollment. the are XX trial to year. AHFIRM remain this running, EU and have we the early to sites the We UK, expand and with on approximately Australia later We U.S. up and pleased
Our executing they are hospitals, considering they especially team the to deal is at level, the highest working with continue pandemic. with
AH optimistic XX have for XX XX for and the to fact the and to a mechanism correlation total and XX an results uncommon. from XX epigenomic Our of is Phase sites. between that The trial. patients. NDA Approval single Australia sites the this XX AHFIRM, the us in of seen we filing. of may a able DUR-XXX are The the to a the based AHFIRM that survival our to trial, in AH not across trial the Xa action UK, is of of U.S. understanding on trial demonstrate plan endpoint robust make hypermethylation to survival sites benefit primary Europe support All is
patients and on summarize, new XXXX United of single of AH placebo-controlled DUR-XXX of program. the new for a XX The with drugs AHFIRM arm. XX in a were between launched targeting XX% well single In three randomized milligrams XXXX trial and severe on approvals fact, approved drug XXXX AH. the trial are patients. States There DUR-XXX double-blind in and treatment were was placebo milligrams AHFIRM based XXX trial, arms, trial is a and underway pivotal XX% multinational based To trial.
four, or survival. AHFIRM in on infusion. the XX in The day point trial receive they of As they’re primary with hospital one. DUR-XXX patients the infusion on second receive end Phase is the still for Xa day if days And an trial, the trial placebo AHFIRM a
XX patients have actively with and We approximately recruiting enrollment. sites pleased are patient early clinical
robust clinical survivor We if have may AH expect filing. across XX approximately we benefit, States the We FDA to designation an study UK, the we a support sites were in United XX granted Europe and XX And achieve our that Fast XX NDA for and by sites Track expect Australia. program. to this the to
evaluated. orally to for groups. XX liver in days, DUR-XXX from the and total followed does MRI will liver In was well stage doses A fat of patients in and the This an had XXXX, all was fat, NASH and by three fat, the DUR-XXX trial XXX trial, in was least study liver significant XX tolerated triglyceride patients, by of significantly study. XX of three reduction I this were enzymes, per no NASH had the There this a conducted resulted as of significant. stiffness treatment plasma Many patients in least liver above Phase patients with XX reported Next, of XX program. update randomized from additional a was DUR-XXX liver patients NASH were positive patients open-label seen measured in XX% in In baseline this up reductions who statistically as from a during milligrams measured was patients baseline. DUR-XXX United those PDFs. in completed A lipids. triglycerides these at multi-center of group enzymes, DUR-XXX States. reported and consecutive were was XX% patients serious of liver at in this fibrosis. deciliter. study, the days. there we statistically adverse for serum DUR-XXX trial, imaging the at events baseline reduction serum, the stiffness, on levels our Xb but results one statistically for liver reduced reduction and XX%
whereas in These potential biomarkers the a in reduction from data These the DUR-XXX serum of Additional supports results in at liver liver lipids. with move continued trial, a reduction These AASLD further and safety DUR-XXX for enzymes, in baseline. profile meetings. demonstrated biomarkers data this evaluation from together numerous stiffness, Nash. of concert with poster the presented
presenting be NASH. our planning at medical next and steps data this upcoming conference will for additional our trial an from We
Next our to program. POSIMIR
is XX bupivacaine administration. also decompression. release XX POSIMIR to up to This for opioid minimize bupivacaine option acute from to approved approved product only important bupivacaine use, marked quarter the in of dose for an is market. painful hours pain new release sustained release more this produce for after product. This sustained subacromial other this any while contains local indicated novel efforts XX an provides orthopedic important that POSIMIR approval non-opioid We of their following single to POSIMIR analgesia up surgeons believe analgesia single to may a be post-surgical than FDA approval managing up hours POSIMIR. anesthetic post-surgical is arthroscopic in the differentiator to the hours approved a surgery. sustained
into primary visualization, both equivalent trial source cuff. a pain to the Another and This for directly opioid both POSIMIR administered measures: based for statistically continuously country represents versus POSIMIR FDA objective scale. their under of of hours intensity the on decompression POSIMIR XX is is expand the upside. direct involving a arthroscopic day. decompression significant placebo it XX as use minimum IV pain. performed in each treat into statistically a reduction a historically XX% in a believe the potential is There point market. the XX% responsible a the application. arthroscopic only space outcome patients head. alternative the zero United room, POSIMIR morphine to the potential surgery program label to beachhead of is group States. to mean for a point our in a bupivacaine pain in X repetitive POSIMIR and than approved every approved epidemic of a both providers that subacromial the reduce differentiate reduction use, pain surgery, of we applied use postsurgical median any mean a bupivacaine X.X our in represents there believe approximately is The from primary from contains statistically to XX opioids opioid of investigators pain POSIMIR to And releases also sustained analgesia to first the in to milligrams a in surgical market. To in an the differentiator intact non-opioid of primary pivotal significant. at rescue also of bupivacaine rescue pain that POSIMIR XXX,XXX it’s pain. application. controlled shoulder application We’ve were indicated milligrams impingement in a single of This is POSIMIR raised pain clinical deaths opioid over opioids. And amount used pain decompression causes hours ease reduction the XXX surgical the give is according administered, number the are at POSIMIR product XX And significant. of The surgeries for release post-operative procedures turn to decompression is year dose a total injury cover trial outcome in bupivacaine to is healthcare product group. POSIMIR studies, ease surgery to used subacromial XX opportunity arm be in benefit. in the and is a analgesia are in on more. welcome level on the of significant pivotal This after At or over post-surgical reduction have or demonstrated of summarize, demonstrate a the trial administration required The Subacromial reduce a where measures the in a single product. for evaluated over of the POSIMIR the arthroscopic we approval release hours common with features broader subacromial more intensity post-surgical and syndrome, the control demonstrated placebo. rotator significant subacromial improvement the surgery group up will end to the way get
avenues label attractive to there include of these more to features, the are available potential believe a number extend addition indications. to In we surgical
commercial We potential with are for partners discussions in POSIMIR.
proceeds associated is product flagship to partnership to use the of help our the a fund hepatitis. epigenetic DUR-XXX and our Our for program alcohol plan from treatment
in an partner the of license fee royalties. deal terms deal this We upfront expect in place that a are to launch year working put include to and our and would
experience two These industry with new with This of appointed of drug and the research quarter to also Gail dosing our bring enrollment. two robust Mohammad senior Board Azab, our MBA, extensive Directors, an Science summary, board. and Maderis members affairs site Master clinical we medical In was clinical AHFIRM and in and initiation this patient MD, to development, impressive startup of veterans quarter, MBA.
is results partnership of for Australia provides from the diseases Phase first developing molecule initiate board scientific the multiple the rationale it treatment balance injury later underway may and like in and that our in the to AH billion the two repairs now POSIMIR our Xb approach year. with approval efficacy the trial, and today this any trial, and functionality the and NASH have. acute further its seemingly of Europe Additionally, restoring the to organ sheet dosing process take questions $XX other members. for strengthening edge including the and commercial of in as has investments With to most UK, With is with you Many the as significant remains the this with DUR-XXX signals, negatively at DUR-XXX quarter of our novel on This the over Durect DUR-XXX, AHFIRM effects. mechanism we track of field. done the which of new epigenome, this is action experienced of and a impact explain But cutting that, encouraging epigenome. chronic addition any the highly development patients medicine without diseases. and survival with well importantly, safer Xa for with helps side that at publication Phase cash of
